Prosecution Insights
Last updated: November 06, 2026
Application No. 19/101,012

PROCESSES FOR PREPARING OXAZOLIDINONE COMPOUNDS

Non-Final OA §112
Filed
Feb 04, 2025
Priority
Aug 10, 2022 — provisional 63/396,829 +1 more
Examiner
ROBINSON, MIKHAIL O'DONNEL
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Werthenstein Biopharma GmbH
OA Round
1 (Non-Final)
59%
Grant Probability
Moderate
1-2
OA Rounds
1y 7m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
78 granted / 133 resolved
-1.4% vs TC avg
Strong +43% interview lift
Without
With
+42.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
57 currently pending
Career history
187
Total Applications
across all art units

Statute-Specific Performance

§101
4.9%
-35.1% vs TC avg
§103
40.6%
+0.6% vs TC avg
§102
21.6%
-18.4% vs TC avg
§112
22.7%
-17.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 133 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action Claims 1-9, 12-15, 17-19, 21-27, 29-34 and 36 are pending and now evaluated on its merits. Priority This application claims U.S. domestic benefit to provisional application 63/396,829, dated 08/10/2022. Information Disclosure Statement The information disclosure statement (IDS) dated 03/20/2025 complies with the provisions of 37 CFR 1.97, 1.98 and MPEP § 609. Accordingly, it has been placed in the application file and the information therein has been considered as to the merits. Specification Applicants specification (Pg. 20) makes reference to the process disclosed in WO 2021/000684 of the clamed structure PNG media_image1.png 137 213 media_image1.png Greyscale . The mentioned publication makes no reference to the process nor the above structure, instead the process is disclosed in WO 2021188606 A1. Proper correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 15, 19, 23 and 26 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claims 15, 19, 23 and 26, the phrase "Fig. 2, Fig. 3, Fig.5, Fig. 6, Fig.8, Fig.9, Fig.11 and Fig. 12" renders the claims indefinite because it is unclear what are the limitations to the above figures as the figures are not presented or described in the claims. Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter: Claims 1-9, 12-14, 17-18, 21-22, 24-25, 27, 29-34 and 36 are free of the arts. The closest prior art is Crowley et al. (WO 2021188606 A1). Crowley teaches PNG media_image2.png 422 676 media_image2.png Greyscale (example 1) as a method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis (abstract). The teachings of Crowley differs from claimed invention of the process of treating a compound of Formula 5a PNG media_image3.png 113 188 media_image3.png Greyscale and/or 5b PNG media_image4.png 118 194 media_image4.png Greyscale with methyl (S)-(3-chloro-2-hydroxypropyl)carbamate to produce PNG media_image1.png 137 213 media_image1.png Greyscale . Additionally, Crowley fails to teach PNG media_image1.png 137 213 media_image1.png Greyscale in crystalline form and structure PNG media_image5.png 89 121 media_image5.png Greyscale . Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MIKHAIL O'DONNEL ROBINSON whose telephone number is (571)270-0777. The examiner can normally be reached Monday-Friday 7:30am-5:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. MIKHAIL O'DONNEL. ROBINSON Examiner Art Unit 1627 /MIKHAIL O'DONNEL ROBINSON/Examiner, Art Unit 1627 /SARAH PIHONAK/Primary Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Feb 04, 2025
Application Filed
Oct 28, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780781
Methods of Making Deuterium-Enriched N-Acetylcysteine Amide (D-NACA) and (2R,2R)-3,3-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
3y 4m to grant Granted Nov 03, 2026
Patent 12774282
OXASPIRO SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVE, INTERMEDIATE THEREOF, AND PREPARATION METHOD THEREFOR
3y 4m to grant Granted Oct 27, 2026
Patent 12746257
IRON SUPPLEMENT COMPOSITIONS AND METHODS OF USE THEREOF
1y 7m to grant Granted Sep 29, 2026
Patent 12734173
USE OF NUCLEOTIDE SYNTHESIS INHIBITORS FOR TARGETED THERAPY IN MLL3/4 COMPASS MUTANT CANCER
3y 3m to grant Granted Sep 15, 2026
Patent 12728128
COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS
4y 10m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
59%
Grant Probability
99%
With Interview (+42.6%)
3y 4m (~1y 7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 133 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month